BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for cardiovascular and renal disease, announced today that the first patient was enrolled in its Phase II clinical study with Bendavia™ for the treatment of acute kidney injury (AKI) and renal microvascular dysfunction in hypertension. The study was initiated based on Bendavia research showing “unique therapeutic potential for improving kidney function and outcomes,” as published in the American Heart Association journal, Hypertension. Several prior clinical studies demonstrated that Bendavia appears to be safe and well–tolerated with no serious adverse events across a broad dose range with highly predictable pharmacokinetics.
